Willett Advisors — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Cellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies.
Advanced ManufacturingBiotechMedical DevicesSouth San Francisco, US
Fabian Gerlinghaus(Co-Founder and Chief Executive Officer)inOmar Kurdi(Co-Founder and President)in
BoardJustin Butler(Director)inVictor Tong(Director)in
Co-investorsDecheng Capital8VCEcoR1 CapitalIntuitive VenturesKoch Disruptive TechnologiesBaillie Gifford+4 more
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investors5AM VenturesAtlas VentureRA CapitalEQT Life SciencesSixty Degree CapitalVivo Capital+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.